TY - JOUR
T1 - Development and Validation of a Short Version of the Metric for the Observation of Decision-Making in Multidisciplinary Tumor Boards
T2 - MODe-Lite
AU - Lamb, B. W.
AU - Miah, S.
AU - Skolarus, T. A.
AU - Stewart, G. D.
AU - Green, J. S.A.
AU - Sevdalis, N.
AU - Soukup, T.
N1 - Funding Information:
GDS is supported by The Mark Foundation for Cancer Research, the Cancer Research UK Cambridge Centre [C9685/A25177] and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). BWL and TS have previously received funding from Cancer Alliances, NHS England, and Health Education England for training cancer MDTs in assessment and quality improvement methods in the United Kingdom. TS also received fees from Roche Diagnostics for research services in relation to innovations for cancer MDTs in the United States of America. N. Sevdalis is the Director of London Safety & Training Solutions, Ltd, which provides team-working, patient safety, and improvement skills training and advice on a consultancy basis to hospitals and training programs in the UK and internationally. J. S. A. Green is a Director of Green Cross Medical Ltd that developed MDT FIT for use by National Health Service Cancer Teams in the UK. G. D. Stewart has received educational grants from Pfizer, AstraZeneca, and Intuitive Surgical; consultancy fees from Merck, Pfizer, EUSA Pharma, and CMR Surgical; travel expenses from Pfizer; and speaker fees from Pfizer. T. A. Skolarus receives authorship royalties from UpToDate. S. Miah has no competing interests to declare.
Funding Information:
The research of N. Sevdalis is funded by the NIHR via the Applied Research Collaboration: South London at King's College Hospital NHS Foundation Trust, London, UK. N. Sevdalis is also is a member of King's Improvement Science, which offers co-funding to the NIHR ARC South London and comprises a specialist team of improvement scientists and senior researchers based at King's College London. Its work is funded by King's Health Partners (Guy's and St Thomas? NHS Foundation Trust, King's College Hospital NHS Foundation Trust, King's College London and South London, and Maudsley NHS Foundation Trust), Guy's and St Thomas? Charity, and the Maudsley Charity. The funding agreement ensured the authors? independence in designing the study, interpreting the data, writing, and publishing the report. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or the Department of Health and Social Care. GDS is supported by The Mark Foundation for Cancer Research, the Cancer Research UK Cambridge Centre [C9685/A25177] and NIHR Cambridge Biomedical Research Centre (BRC-1215- 20014). T. Soukup is supported by the Welcome Trust and Diabetes UK. T. A. Skolarus is supported by the US National Cancer Institute (R01 CA242559 and R37 CA222885). B. W. Lamb, S. Miah, and J. S. A. Green received no funding for this study. We thank the participating tumor boards for their time and commitment.
Funding Information:
The research of N. Sevdalis is funded by the NIHR via the Applied Research Collaboration: South London at King's College Hospital NHS Foundation Trust, London, UK. N. Sevdalis is also is a member of King's Improvement Science, which offers co-funding to the NIHR ARC South London and comprises a specialist team of improvement scientists and senior researchers based at King's College London. Its work is funded by King's Health Partners (Guy's and St Thomas’ NHS Foundation Trust, King's College Hospital NHS Foundation Trust, King's College London and South London, and Maudsley NHS Foundation Trust), Guy's and St Thomas’ Charity, and the Maudsley Charity. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or the Department of Health and Social Care. GDS is supported by The Mark Foundation for Cancer Research, the Cancer Research UK Cambridge Centre [C9685/A25177] and NIHR Cambridge Biomedical Research Centre (BRC-1215- 20014). T. Soukup is supported by the Welcome Trust and Diabetes UK. T. A. Skolarus is supported by the US National Cancer Institute (R01 CA242559 and R37 CA222885). B. W. Lamb, S. Miah, and J. S. A. Green received no funding for this study. We thank the participating tumor boards for their time and commitment.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/11
Y1 - 2021/11
N2 - Background: Evidence-based tools are necessary for scientifically improving the way MTBs work. Such tools are available but can be difficult to use. This study aimed to develop a robust observational assessment tool for use on cancer multidisciplinary tumor boards (MTBs) by health care professionals in everyday practice. Methods: A retrospective cross-sectional observational study was conducted in the United Kingdom from September 2015 to July 2016. Three tumor boards from three teaching hospitals were recruited, with 44 members overall. Six weekly meetings involving 146 consecutive cases were video-recorded and scored using the validated MODe tool. Data were subjected to reliability and validity analysis in the current study to develop a shorter version of the MODe. Results: Phase 1, a reduction of the original items in the MODe, was achieved through two focus group meetings with expert assessors based on previous research. The 12 original items were reduced to 6 domains, receiving full agreement by the assessors. In phase 2, the six domains were subjected to item reliability, convergent validation, and internal consistency testing against the MODe-Lite global score, the MODe global score, and the items of the MODe. Significant positive correlations were evident across all domains (p < 0.01), indicating good reliability and validity. In phase 3, feasibility and high inter-assessor reliability were achieved by two clinical assessors. Six domains measuring clinical input, holistic input, clinical collaboration, pathology, radiology, and management plan were integrated into MODe-Lite. Conclusions: As an evidence-based tool for health care professionals in everyday practice, MODe-Lite gives cancer MTBs insight into the way they work and facilitates improvements in practice.
AB - Background: Evidence-based tools are necessary for scientifically improving the way MTBs work. Such tools are available but can be difficult to use. This study aimed to develop a robust observational assessment tool for use on cancer multidisciplinary tumor boards (MTBs) by health care professionals in everyday practice. Methods: A retrospective cross-sectional observational study was conducted in the United Kingdom from September 2015 to July 2016. Three tumor boards from three teaching hospitals were recruited, with 44 members overall. Six weekly meetings involving 146 consecutive cases were video-recorded and scored using the validated MODe tool. Data were subjected to reliability and validity analysis in the current study to develop a shorter version of the MODe. Results: Phase 1, a reduction of the original items in the MODe, was achieved through two focus group meetings with expert assessors based on previous research. The 12 original items were reduced to 6 domains, receiving full agreement by the assessors. In phase 2, the six domains were subjected to item reliability, convergent validation, and internal consistency testing against the MODe-Lite global score, the MODe global score, and the items of the MODe. Significant positive correlations were evident across all domains (p < 0.01), indicating good reliability and validity. In phase 3, feasibility and high inter-assessor reliability were achieved by two clinical assessors. Six domains measuring clinical input, holistic input, clinical collaboration, pathology, radiology, and management plan were integrated into MODe-Lite. Conclusions: As an evidence-based tool for health care professionals in everyday practice, MODe-Lite gives cancer MTBs insight into the way they work and facilitates improvements in practice.
UR - http://www.scopus.com/inward/record.url?scp=85104820532&partnerID=8YFLogxK
U2 - 10.1245/s10434-021-09989-7
DO - 10.1245/s10434-021-09989-7
M3 - Article
C2 - 33974197
AN - SCOPUS:85104820532
SN - 1068-9265
VL - 28
SP - 7577
EP - 7588
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 12
ER -
